Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health Inc (NY: HIMS )

22.15 +0.59 (+2.74%)
Official Closing Price Updated: 7:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,348,404
Open 21.76
Bid (Size) 22.10 (1)
Ask (Size) 22.15 (10)
Prev. Close 21.56
Today's Range 21.10 - 22.16
52wk Range 5.650 - 25.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Hims & Hers' Incredible Growth Will Continue
GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is. 
Via The Motley Fool
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
Hims & Hers has enjoyed a rally on an FDA decision regarding Eli Lilly's tirzepatide. 
Via Investor's Business Daily
Exposures Product Safety

Performance

YTD
+129.77%
+129.77%
1 Month
+35.81%
+35.81%
3 Month
+14.06%
+14.06%
6 Month
+86.13%
+86.13%
1 Year
+266.12%
+266.12%

More News

Read More
Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024
From Hims & Hers
Via Business Wire
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
Via Benzinga
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
Via Investor's Business Daily
Topics Lawsuit
Exposures Financial Legal Product Safety
What Is Going On With Hims & Hers Stock?
Via The Motley Fool
Where Does Hims & Hers Stock Go From Here?
Via The Motley Fool
Exposures Product Safety
2 Incredibly Cheap Growth Stocks to Buy Right Now
Via The Motley Fool
2 No-Brainer Growth Stocks to Buy With $500 Right Now
Via The Motley Fool
Top 3 Stocks with Explosive Call Option Activity: What to Watch
Via MarketBeat
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
Via Benzinga
Exposures Product Safety
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
Via MarketBeat
Topics Stocks
Exposures US Equities
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
Via Benzinga
Hims & Hers Health Stock Is Rising Monday: What's Going On?
Via Benzinga
Topics Stocks
Exposures US Equities
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Via Benzinga
Exposures Product Safety
Massive News for Hims & Hers Stock: The Truth About Today's Move
Via The Motley Fool
2 Winning Growth Stocks That Are Screaming Buys Right Now
Via The Motley Fool
AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday
Via Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer
Via The Motley Fool
Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel
Via Benzinga
Hims & Hers to Offer Access to Compounded GLP-1 Injections for as Low as $99/Month to U.S. Military, Veterans, Teachers, Nurses and First Responders
From Hims & Hers
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.